Prostate Cancer - What's New?
- PMID: 27408081
- PMCID: PMC4921738
- DOI: 10.1016/S0377-1237(08)80149-9
Prostate Cancer - What's New?
Abstract
Research has shown that prostate specific antigen (PSA) is a tumour marker for diagnosis of cancer prostate with significant prognostic value. Screening studies in North America and Europe have revealed that carcinoma prostate is common. Early detection and treatment improves the quality of life besides preventing deaths due to metastatic prostate cancer. Radical prostatectomy and laparoscopic radical prostatectomy has become the standard treatment for localized prostate cancer in all major uro-oncological centres resulting in reduced mortality. Magnetic resonance imaging and positron emission tomography have helped in detecting local and distant spread of cancer prostate. Revised approach to reduce occurrence of prostate cancer by the use of 5 alpha reductase inhibitors like finasteride and dietary supplements has been instituted. The World Health Organisation (WHO) has recommended lifestyle changes to promote men's health and reduce the incidence of prostate cancer.
Keywords: Prostate cancer; Prostate specific antigen; Radical prostatectomy; Watchful waiting.
Similar articles
-
Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.Prescrire Int. 2012 Oct;21(131):242-8. Prescrire Int. 2012. PMID: 23185849 Review.
-
68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.Eur Urol Focus. 2018 Sep;4(5):686-693. doi: 10.1016/j.euf.2016.11.002. Epub 2016 Nov 15. Eur Urol Focus. 2018. PMID: 28753806
-
The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.Contemp Clin Trials. 2009 Jan;30(1):81-7. doi: 10.1016/j.cct.2008.08.002. Epub 2008 Aug 23. Contemp Clin Trials. 2009. PMID: 18783735 Clinical Trial.
-
Prostate specific antigen only progression of prostate cancer.J Urol. 2000 Jun;163(6):1632-42. J Urol. 2000. PMID: 10799151 Review.
-
More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003
References
-
- Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE. Measurement of prostate specific antigen in serum as a screening test for prostate cancer. N Eng J Med. 1991;324:1156–1161. - PubMed
-
- Jemal A, Murray T, Samuels A, Tiwari RC, Ward E. Cancer Statistics, 2005. CA Cancer J Clin. 2005;55:10–30. - PubMed
-
- Freedland SJ, Aronson WJ. Obesity and prostate cancer. Urol. 2005;65:433–439. - PubMed
-
- Eduardo IC, Shahrokh FS, Kevin MS. Molecular diagnosis of Prostate cancer. Current Prostate Reports Oct. 2004;4:11–17.
-
- Schmitz M, Grignard G, Margue C, Dippel W, Capesius C. Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. Int J Cancer. 2007;120:1284–1292. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous